Trichostatin A-induced apoptosis is mediated by krüppel-like factor 4 in ovarian and lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 16, 2014, Pages 6581-6586

  Zohre, Sadeghi ^a,b   Kazem, Nejati Koshki ^b   Abolfazl, Akbarzadeh ^b   Mohammad, Rahmati Yamchi ^a,c   Aliakbar, Movassaghpour ^c   Alizadeh, Effat ^b   Zahra, Davoudi ^b   Hassan, Dariushnejad ^b   Nosratollah, Zarghami ^a,b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Histone deacetylase inhibitor; klf4; Trichostatin A

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 4; TRICHOSTATIN A;

APOPTOSIS; BIOSYNTHESIS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; HUMAN; LUNG NEOPLASMS; METABOLISM; OVARIAN NEOPLASMS; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; UP-REGULATION;

EID: 84906827731     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.16.6581     Document Type: Article

References (70)

1. Ai W, Liu Y, Langlois M, Wang TC (2004). Kruppel-like factor 4 (KLF4) represses histidine decarboxylase gene expression through an upstream Sp1 site and downstream gastrin responsive elements. J Biol Chem, 279, 8684-93.
2. Akbarzadeh A, Ghasemali S, Nejati K, et al (2013). Study of inhibitory effect of β-cyclodextrin-helenalin complex on HTERT gene expression in T47D breast cancer cell line by real time quantitative PCR (q-PCR). Asian Pac J Cancer Prev, 14, 6949-53.
3. Akbarzadeh A, Hosseininasab S, Davaran S, et al (2014). Synthesis, characterization, and In vitro studies of PLGA-PEG nanoparticles for oral Insulin delivery. Chem Biol Drug Des, 3, 1-9.
4. Akbarzadeh A, Mikaeili H, Zarghami N, et al (2012). Preparation and in-vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymer. Int J Nanomedicine, 7, 1-16.
5. Akbarzadeh A, Nejati-Koshki K, Mahmoudi Soghrati M, et al (2013). In vitro studies of NIPAAM-MAA-VP copolymercoated magnetic nanoparticles for controlled anticancer drug release. JEAS, 3, 108-15.
6. Akbarzadeh A, Omidfar K, Ahmadin A, et al (2014). An electrochemical immunosensor for digoxin using core-shell gold coated magnetic nanoparticles as labels. Mol Biol Rep, 41, 1659-68.
7. Akbarzadeh A, Pourhassan-Moghaddam M, Rahmati-Yamchi M, et al (2013). Protein detection through different platforms of immuno-loop-mediated isothermal amplification. Nanoscale Res Lett, 8, 485-95.
8. Akbarzadeh A, Rezaei A, Nejati-Koshki K, et al (2014). Synthesis and physicochemical characterization of biodegradable star-shaped poly lactide-co-glycolide- β -cyclodextrin copolymer nanoparticles containing albumin. J Adv Nanoparticles, 3, 1-9.
9. Akbarzadeh A, Rezaei-Sadabady R, Zarghami N, et al (2013). Studies of the relationship between structure and antioxidant activity in interesting systems, including tyrosol, hydroxytyrosol derivatives indicated by quantum chemical calculations. Soft, 2, 13-8.
10. Akbarzadeh A, Samiei M, Davaran S, et al (2012). Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett, 7, 14-26.
11. Akbarzadeh A, Samiei M, Joo SW, et al (2012). Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. J Nanobiotechnol, 10, 46-52.
12. Akbarzadeh A, Zarghami N, Mikaeili H, et al (2012). Synthesis, characterization and in vitro evaluation of novel polymercoated magnetic nanoparticles for controlled delivery of doxorubicin. Nanotechnol Sci Appl, 5, 13-25.
13. Aksoy I, Giudice V, Delahaye E, et al (2014). Klf4 and Klf5 differentially inhibit mesoderm and endoderm differentiation in embryonic stem cells. Nat Commun, 5, 1-15.
14. Bellarosa D, Bressan A, Bigioni M, et al (2012). SAHA/ Vorinostat induces the expression of the CD137 receptor/ ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Int J Oncol, 41, 1486-94.
15. Butler LM, Agus DB, Scher HI, et al (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res, 60, 165-70.
16. Butler LM, Webb Y, Agus DB, et al (2001). Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res, 7, 962-70.
17. Chen X, Erika MW, Gao SY, Yang VW (2003). Transcriptional profiling of Krüppel-like factor 4 reveals a function in cell cycle regulation and epithelial differentiation. J Mol Biol, 326, 665-77.
18. Chen Z, Clark S, Birkeland M, et al (2002). Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett, 188, 127-40.
19. Chen ZY, Shie J, Tseng C (2000). Up-regulation of gut-enriched kruppel-like factor by interferon-gamma in human colon carcinoma cells. FEBS Lett, 477, 67-72.
20. Chen ZY, Rex S, Tseng CC (2004). Kruppel-like factor 4 is transactivated by butyrate in colon cancer cells. J Nutr, 134, 792-8.
21. Cheng DD, Yang QC, Zhang ZH, Yang CX, Liu YW (2012). Antitumor activity of histone deacetylase inhibitor trichostatin a in osteosarcoma cells. Asian Pac J Cancer Prev, 13, 1395-9.
22. Choi BJ, Cho YG, Song JW, et al (2006). Altered expression of the KLF4 in colorectal cancers. Pathology Res Pract, 202, 585-9.
23. Choudhary C, Kumer C, Gnad F, et al (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 325, 834-40.
24. Cress WD, Seto E (2000). Histone Deacetylases, Transcriptional Control, and Cancer. J Cell Physiol, 184, 1-16.
25. Ebrahimnezhad Z, Zarghami N, Keyhani M, et al (2013). Inhibition of hTERT gene expression by silibinin-loaded PLGA-PEG-Fe3O4 in T47D breast cancer cell line. Bioimpacts, 3, 67-74.
26. Feng L, Pan M, Sun J, et al (2013). Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells. J Mol Med, 91, 49-58.
27. Francisco R, Perez-Perarnau A, Cortes C, et al (2012). Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer Lett, 1, 42-52.
28. Ghasemali S, Nejati-Koshki K, Tafsiri E, et al (2013). Inhibitory effects of β-cyclodextrin-helenalin complexes on H-TERT gene expression in the T47D breast cancer cell line - results of real time quantitative PCR. Asian Pac J Cancer Prev, 14, 6949-53.
29. Glaser KB, Staver MJ, Waring JF, et al (2003). Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MD acarcinoma cell lines. Mol Cancer Ther, 2, 151-63.
30. Glaser KB (2007). HDAC inhibitor: clinical update and mechanism-based potential. Biochem Pharmacol, 74, 659-71.
31. Herold C, Ganslmayer M, Ocker M, et al (2002). The histone-deacetylase inhibitor trichostatin a blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol, 36, 233-40.
32. Horing E, Podlech O, Silkenstedt B, et al (2013). The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells. Anticancer Res, 33, 1351-60.
33. Liu T, Kulijaca S, Tee A, Marshall GM (2006). Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev, 32, 157-65.
34. Marks PA, Richard A, Rifkind RA (2000). Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Nati Cancer Inst, 92, 1210-6.
35. Mees S, Nemunai J, Senzer N (2009). Transcription factors: their potential as targets for anindividualized therapeutic approach to cancer. Cancer Gene Ther, 16, 103-12.
36. Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al (2013). PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev, 14, 6925-8.
37. Nejati-Koshki K, Zarghami N, Pourhassan-Moghaddam M, et al (2012). Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors. Cytotechnology, 64, 719-26.
38. Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghaddam M, et al (2013). Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pac J Cancer Prev, 14, 6595-9.
39. Nasiri M, Zarghami N, Koshki KN, et al (2013). Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev,14, 3449-53.
40. Ohnishi S, Ohnami S, Laub F, et al (2003). Downregulation and growth inhibitory effect of epithelial-type Kruppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun, 308, 251-6.
41. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB (1998). Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem, 273, 10696-701.
42. Peiffer L, Poll-Wolbeck SJ, Flamme H, et al (2014). Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation. J Cancer Res Clin Oncol, [Epub ahead of print]
43. Piacentini P, Conadelli M, Costanzo C, et al (2006). Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch, 448, 797-804.
44. Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H (2007). The HDAC inhibitor trichostatin a inhibits growth of small cell lung cancer cells. J Surg Res, 142, 219-26.
45. Pourhassan-Moghaddam M, Rahmati-Yamchi M, Akbarzadeh A, et al (2013). Protein detection through different platforms of immuno-loop-mediated isothermal amplification. Nanoscale Res Lett, 8, 485.
46. Rasheed WK, Johnstone RW, Prince HM (2007). Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs, 16, 659-78.
47. Sadat Tabatabaei Mirakabad F, Nejati-Koshki K, Akbarzadeh A, et al (2014). PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev, 15, 517-35.
48. Sawa H, Murakami H, Ohshima Y, et al (2001). Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol, 18, 109-14.
49. Shan Z, Feng-Nian R, Jie G, Ting Z (2012). Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo. Asian Pac J Cancer Prev, 13, 3977-82.
50. Shie JL, Chen ZY, Fu M, Pestell RG, Tseng CC (2000). Gut enriched kruppel-like factor represses cyclin D1 promoter activity through Sp1 motif. Nucleic Acids Res, 28, 2969-76.
51. Shields JM, Christy RJ, Yang VW (2009). Identification and characterization of a gene encoding a gut-enriched Kruppel-like factor expressed during growth arrest. J Biol Chem, 271, 20009-17.
52. Sonnemann J HI, Sigler M, Palani CD, et al (2008). Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells. Oncol Rep, 20, 219-24.
53. Van LC, Verdin E, Verdin E (1996). Expression of a small fraction of cellular genes is changed in response to histone hyperacetylation, Gene Expr, 5, 245-53.
54. Vigushin DM, Ali S, Pace PE, et al (2001). Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res, 7, 971-76.
55. Wang F, Qi Y, Li X, et al (2013). HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9. Clin Invest Med, 36, 87-94.
56. Wang J, Place RF, Huang V, et al (2010). Prognostic value and function of KLF4 in prostate cancer: RNAa and vector mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res, 70, 10182-91.
57. Wei D, Gong W, Kanai M, et al (2005). Drastic down-regulation of Kruppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res, 65, 2746-54.
58. Wei D, Kanai M, Jia Z, Le X, Xie K (2008). Krüppel-like Factor 4 induces p27Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res, 68, 4631-9.
59. Weichert W, Roske A, Gekeler V, et al (2008). Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer, 98, 604-10.
60. Wilson AJ, Holson E, Wagner F, et al (2011). The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther, 12, 484-93.
61. Wu ZQ, Zhang R, Chao C, Zhang JF, Zhang YQ (2007). Histone deacetylase inhibitor trichostatin A induced caspase-independent apoptosis in human gastric cancer cell. Chin Med J, 120, 2112-8.
62. Yoon HS, Chen X, Yang VW (2003). Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J Biol Chem, 278, 2101-5.
63. Yoon HS, Yang VW (2004). Requirement of Kruppel-like factor 4 in preventing entry into mitosis following DNA damage. J Biol Chem, 279, 5035-41.
64. Yoon O, Roh J (2012). Downregulation of KLF4 and the Bcl-2/ Bax ratio in advanced epithelial ovarian cancer. Oncol Lett, 4, 1033-6.
65. Yori JL, Seachrist DD, Johnson E, et al (2011). Kruppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia, 13, 601-10.
66. You BR, Park WH (2013). Trichostatin A induces apoptotic cell death of HeLa cells in a Bcl-2 and oxidative stress-dependent manner. Int J Oncol, 42, 359-66.
67. Yu F, Li J, Chen H, et al (2011). Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene, 30, 2161-72.
68. Zhang QC, Jiang SJ, Zhang S, Ma XB (2012). Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 Cell Line. Asian Pac J Cancer Prev, 13, 3471-6.
69. Zhang S, Zhang QC, Jiang SJ, Chin SJ (2013). Effect of trichostatin A and paclitaxel on the proliferation and apoptosis of lung adenocarcinoma cells. Chin Med J, 126, 129-34.
70. Zhang W, Geiman DE, Shields JM (2000). The gut enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J Biol Chem, 275, 18391-8.